|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2009-11-27
|
|
pubmed:abstractText |
Computer-assisted morphometry can provide precise measurement of hepatic fibrosis on a continuous scale. Previous morphometric studies of large cohorts of patients with treatment refractory chronic hepatitis C have shown a mean increase in fibrosis of 30% to 58% in 1 year. The aim of the present study was to quantify fibrosis progression in biopsy specimens obtained over 1.5 to 5 years from three groups of patients with baseline bridging fibrosis or cirrhosis (Ishak stages 3-6) enrolled in the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial. The main group of 346 lead-in nonresponders (viremic after 24 weeks of peginterferon-ribavirin therapy) had a mean fibrosis increase of 61% over pretreatment baseline after 2 years and 80% after 4 years. In contrast, the 78 breakthrough/relapse patients (undetectable serum hepatitis C virus RNA after 24 weeks of peginterferon-ribavirin and receiving antiviral therapy for 48 weeks) showed a mean increase in fibrosis of 48% when biopsied 36 months from pretreatment baseline but no further increase at 60 months. Finally, the 111 express patients with baseline biopsies following unsuccessful peginterferon-ribavirin outside the trial had significantly more baseline fibrosis than the others but an increase of only 21% after 21 months and a slight decrease at 45 months. Maintenance therapy with low-dose peginterferon had no effect on fibrosis changes in any of the groups. CONCLUSION: Morphometry demonstrated complex, nonlinear changes in fibrosis over time in this heterogeneous cohort of patients with interferon-refractory chronic hepatitis C.
|
|
pubmed:grant |
http://linkedlifedata.com/resource/pubmed/grant/01-DK-9-2319,
http://linkedlifedata.com/resource/pubmed/grant/1 UL1 RR 025780-01,
http://linkedlifedata.com/resource/pubmed/grant/1 UL1 RR024982-01,
http://linkedlifedata.com/resource/pubmed/grant/1 UL1 RR024986,
http://linkedlifedata.com/resource/pubmed/grant/1 UL1 RR025758-01,
http://linkedlifedata.com/resource/pubmed/grant/M01RR-00042,
http://linkedlifedata.com/resource/pubmed/grant/M01RR-00043,
http://linkedlifedata.com/resource/pubmed/grant/M01RR-00051,
http://linkedlifedata.com/resource/pubmed/grant/M01RR-00065,
http://linkedlifedata.com/resource/pubmed/grant/M01RR-00633,
http://linkedlifedata.com/resource/pubmed/grant/M01RR-00827,
http://linkedlifedata.com/resource/pubmed/grant/M01RR-01066,
http://linkedlifedata.com/resource/pubmed/grant/M01RR-06192,
http://linkedlifedata.com/resource/pubmed/grant/N01-DK-9-2318,
http://linkedlifedata.com/resource/pubmed/grant/N01-DK-9-2320,
http://linkedlifedata.com/resource/pubmed/grant/N01-DK-9-2321,
http://linkedlifedata.com/resource/pubmed/grant/N01-DK-9-2322,
http://linkedlifedata.com/resource/pubmed/grant/N01-DK-9-2323,
http://linkedlifedata.com/resource/pubmed/grant/N01-DK-9-2324,
http://linkedlifedata.com/resource/pubmed/grant/N01-DK-9-2325,
http://linkedlifedata.com/resource/pubmed/grant/N01-DK-9-2326,
http://linkedlifedata.com/resource/pubmed/grant/N01-DK-9-2327,
http://linkedlifedata.com/resource/pubmed/grant/N01-DK-9-2328
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1527-3350
|
|
pubmed:author |
pubmed-author:BonkovskyHerbert LHL,
pubmed-author:BruntElizabeth MEM,
pubmed-author:DienstagJules LJL,
pubmed-author:EversonGregory TGT,
pubmed-author:FontanaRobert JRJ,
pubmed-author:GhanyMarc GMG,
pubmed-author:GoodmanZachary DZD,
pubmed-author:HALT-C Trial Group,
pubmed-author:KleinerDavid EDE,
pubmed-author:LindsayKaren LKL,
pubmed-author:MorganTimothy RTR,
pubmed-author:MorishimaChihiroC,
pubmed-author:ShiffmanMitchell LML,
pubmed-author:StoddardAnne MAM,
pubmed-author:WrightElizabeth CEC
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
50
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1738-49
|
|
pubmed:meshHeading |
pubmed-meshheading:19824074-Adult,
pubmed-meshheading:19824074-Aged,
pubmed-meshheading:19824074-Aged, 80 and over,
pubmed-meshheading:19824074-Collagen,
pubmed-meshheading:19824074-Disease Progression,
pubmed-meshheading:19824074-Female,
pubmed-meshheading:19824074-Hepatitis C, Chronic,
pubmed-meshheading:19824074-Humans,
pubmed-meshheading:19824074-Liver,
pubmed-meshheading:19824074-Liver Cirrhosis,
pubmed-meshheading:19824074-Male,
pubmed-meshheading:19824074-Middle Aged
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial.
|
|
pubmed:affiliation |
Armed Forces Institute of Pathology, Division of Hepatic Pathology and Veterans Administration Special Reference Laboratory for Pathology, Washington, DC, USA. zgoodman@aiplabloratories.com
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
